After a nihilistic period lasting for decades, major progress in nonsmall cell lung cancer (NSCLC) therapy were linked to the introduction of platinum-based regimens, third generation chemotherapeutic drugs and, more recently, with the discovery of oncogenic driver mutations and the development of very effective targeted therapies [1]. However, for a long time, despite known significant immune dysregulations in the lung cancer environment, clinical trials with immune therapy failed to be superior to standard therapy. Adjuvant vaccination was one of the most recent prominent failures [2]. Immunotherapy is a new approach for the treatment of lung cancer with impressive long-term results http://bit.ly/35GVzAn

中文翻译：

---

非小细胞肺癌的免疫治疗：一种新的治疗算法

在经历了数十年的虚无主义时期之后，非小细胞肺癌 (NSCLC) 治疗的重大进展与引入基于铂的方案、第三代化疗药物以及最近发现致癌驱动突变和发展非常有效的靶向治疗[1]。然而，长期以来，尽管已知肺癌环境中存在显着的免疫失调，但免疫治疗的临床试验未能优于标准治疗。辅助疫苗接种是最近最突出的失败之一[2]。免疫疗法是一种治疗肺癌的新方法，具有令人印象深刻的长期效果 http://bit.ly/35GVzAn